Human Longevity Inc. (HLI) Acquires Cypher Genomics, Inc.
(SAN DIEGO, CA)—November 30, 2015—Human Longevity Inc. (HLI), the genomics based, informatics driven company, announced today that the company has acquired Cypher Genomics, Inc., a leading genome informatics company offering highly accurate, rapid and robust human genomic interpretation software solutions. The San Diego-based company has 14 employees who will join HLI including Cypher CEO and co-founder, Ashley Van Zeeland, Ph.D., who is now the head of HLI’s Pediatric Business. Financial details of the deal were not disclosed.
“Cypher Genomics has created important automated and scalable genome interpretation technology informed by additional expertise in genetics and biology that we believe will…Read More
Cypher Genomics Featured as Top Tech Startup To Watch
Cypher Genomics has been featured as one of 12 Tech Startups to Watch in San Diego by Xconomy, a leading source for innovation business news. Cypher’s technology offers a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing.
We have received a number of other recognitions throughout the…Read More
Cypher Genomics Named a San Diego “COOL Company” by San Diego Venture Group
Each year, the San Diego Venture Group selects a small group of nominated start-ups by designating them
Cypher Genomics Named One of San Diego’s MetroConnect Prize Winners
The MetroConnect Prize is part of San Diego Regional Economic Development Corporation’s (EDC’s) Go Global San Diego Initiative, whose mission is to aid in increasing the region’s economic competitiveness and prosperity by helping
Cypher is Proud to be a BeHEARD Technology Sponsor
This spring academic researchers, charitable foundations, and families affected by rare diseases submitted their proposals for the Rare Genomics Institute’s BeHEARD (Helping Empower and Accelerate Research Discoveries) science challenge. Their goal: to win access to leading-edge technologies to advance their research
Cypher Genomics, Clinic for Special Children Collaborate on Rare Disease Diagnoses
Cypher Genomics and the Clinic for Special Children (CSC) today announced a collaboration to diagnose rare genetic diseases.
Strasburg, Pennsylvania-based CSC will use Cypher’s automated genomic interpretation tools to diagnose diseases in its unique patient population, which includes the Amish and Mennonites, populations that have a relatively high incidence of genetic disease.
Celgene to Use Cypher Genomics’ Data Analytics in Drug Development
Under a collaboration announced today, San Diego-based Cypher Genomics said it would use its biomarker discovery service to help New Jersey’s Celgene (NASDAQ: CELG) identify key genetic variants among patients who respond well to specific drugs.
Cypher teams up with biotech titan Celgene for companion diagnostics collaboration
San Diego’s Cypher Genomics has attracted the attention of a biotech legionnaire, teaming up with industry heavyweight Celgene ($CELG) for a companion diagnostics project aimed at uncovering genetic biomarkers that help match patients to a suitable therapy.
Cypher Genomics, U Penn to Collaborate on Genetics Study of Progressive Supranuclear Palsy
Cypher Genomics today announced a collaboration with the University of Pennsylvania to investigate the genetic causes of progressive supranuclear palsy.
CurePSP is funding the research with a grant for an undisclosed amount.
UCSD Hiring ‘Big Data’ Stars
The Broad is surrounded by private companies the serve the “big data” industry. That’s also becoming the case in San Diego, with the rise of such firms as Cypher Genomics, which provide genomics interpretation services.
“Our goal is to help people make sense of complex information in an accurate and meaningful way, and to do so quickly,” said Ashley Van Zeeland, Cypher’s co-founder, and a graduate of UC San Diego’s Rady School of Business.
Cypher Releases Validation Data on CNVs
Cypher Genomics released data last month showing that the company’s Mantis software provided “highly equivalent interpretations” to a panel of genetic counselors when evaluating whether 91 copy number variations (CNVs) detected in non-invasive prenatal testing were pathogenic.
The new data comes just a few months after Cypher announced a development agreement with Sequenom. The prenatal testing company is using Mantis to advance analysis of clinically-relevant fetal sub-chromosomal variants detected in maternal blood.
New Products Posted to GenomeWeb
Cypher Genomics has released a new software update to automate the interpretation of sequencing data from cancer genomes. With the update, Cypher’s Mantis technology will now provide rapid insight into how different genetic variants may impact cancer progression and therapeutic effectiveness, the company said. The update will also provide a summary of somatic and germline variants for single nucleotide variants and small indels, as well as resolve difficult-to-classify variants of unknown significance.
Sequenom Strikes a Deal with Cypher Genomics to Develop Advanced Noninvasive Prenatal Test
Sequenom ($SQNM) is teaming up with Cypher Genomics to develop a noninvasive prenatal test using the company’s advanced genome interpretation screening technology, eyeing a bigger share of an increasingly competitive market. Under the agreement, the San Diego, CA-based company will use Cypher’s Mantis genome interpretation technology to create a new test that susses out clinically relevant fetal subchromosomal variants in maternal blood
San Diego Companies Partner On Prenatal Testing
Through a new partnership the San Diego company behind a prenatal Down syndrome test hopes to offer expectant mothers more information about their pregnancies.
Researchers at the Scripps Translational Science Institute in La Jolla announced today the discovery of a DNA mutation that leads to a severe form of epilepsy.The finding came after the scientists mapped the DNA of a 10-year-old girl who suffers from epileptic encephalopathy.
Cypher Genomics, Sequenom to Partner on Developing Prenatal Tests
Two San Diego companies, Cypher Genomics Inc. and Sequenom Inc., announced an agreement to further develop next-generation noninvasive prenatal tests.
Sequenom, Cypher Genomics Partner on NIPT
NEW YORK (GenomeWeb) – Sequenom and Cypher Genomics have struck a development agreement for noninvasive prenatal testing, the companies said today. Sequenom will use Cypher’s genome interpretation technology, Mantis, to analyze clinically relevant fetal sub-chromosomal variants detected in maternal blood.
Cypher Genomics and Sequenom Announce Agreement on Prenatal Tests
Cypher Genomics Inc. and Sequenom Inc (NASDAQ: SGNM) announced a development agreement for next generation of noninvasive prenatal tests.
Genomics Work Sheds New Light on Girl’s Disease
When Calista Mellos was born 10 years ago, her parents, Sherri and Peter Mellos, knew something was wrong. Unlike the typical noisy baby, Calista didn’t cry when she was hungry. She slept.
We had to really work hard to wake her up,” said her mother, Sherri Mellos. “We’d have to take all of her clothes off, put a fan on her, put cold washcloths on her and constantly rub her feet and face to keep her awake long enough to eat.”
Cypher Genomics Inc. Teams With Illumina, Also Names President and COO
San Diego-based Cypher Genomics Inc. announced a co-promotion agreement with Illumina Inc. and the selection of Adam Simpson as president and chief operating officer. The two companies will jointly offer to pharmaceutical companies, through Illumina’s sales force, a solution including Illumina’s genome sequencing technology and Cypher Genomics’ biomarker discovery service, Cypher said.
Cypher Genomics Signs Deal with Illumina, Expands Executive Team
Cypher Genomics yesterday announced a sales deal with Illumina and added a host of new players to executive board positions. In the deal with Illumina, Illumina’s sales force will promote Cypher’s biomarker discovery service, Coral, to pharmaceutical companies in conjunction with Illumina’s NextBio platform for data analytics and storage. The deal provides a great deal of sales muscle to Cypher, and the companies call the products perfect compliments.
Cypher Genomics’ Analytics Tech Gains Some Cred in Illumina Deal
It’s probably just a matter of time before a new company combines the rapidly advancing technologies of genome sequencing, genetic diagnostics, and Big Data to become the Google of bioinformatics.
Cypher Genomics would like to claim that title, though it’s too early to tell if the three-year-old San Diego startup will be able to pull it off.
Illumina, Cypher Genomics Ink Co-marketing Agreement
NEW YORK (GenomeWeb) – Cypher Genomics has signed a co-promotion agreement with Illumina that lets the sequencing vendor offer Cypher’s Coral biomarker discovery service to pharmaceutical companies.
Illumina, Cypher Genomics to Co-Promote Biomarker Discovery Products
Cypher Genomics and Illumina have made a pact to co-promote Illumina’s sequencing technology, the NextBio platform for data analytics and storage, and Cypher’s Coral™ biomarker discovery service to pharmaceutical companies. The firms, through Illumina’s sales team, will be promoting the products and service together as part of a solution that, they say, can facilitate development of genomic-based biomarkers from whole-genome sequence data for clinical trials and precision medicine.
Cypher Genomics Appoints New President, Board Chair, Directors
San Diego genome informatics company Cypher Genomics Inc., announced on Thursday several leadership appointments, including Adam Simpson as president and chief operating officer.
Genomics Startup Allies with Illumina
A San Diego biotech startup has signed a sales partnership with DNA sequencing giant Illumina and brought on board some prominent industry veterans. Herbert Boyer, a cofounder of Genentech; Henry Nordhoff, former chief executive of Gen-Probe; and Andrew von Eschenbach, a former commissioner of the U.S. Food and Drug Administration, have joined Cypher Genomics, which has 10 employees. Nordhoff becomes executive chairman, and the other two become board directors.
“We Gained Hope.” The Story of Lilly Grossman’s Genome
It started with a slight twitch. Steve and Gay Grossman both noticed it in their daughter Lilly in 1998, when she was just one-and-a-half years old. By the time she was four, the twitches had grown into full-blown muscle tremors. They wracked her whole body at night and were painful enough to wake her up.